Placeholder Banner

Biotech Patenting Event: BIO’s 2012 Fall IPCC in Charleston, South Carolina

October 24, 2012
BIO's 2012 Fall IPCC Conference event on November 12-14 gathers biotech in-house counsels to provide and discuss relevant IP developments.  The Honorable Jimmie V. Reyna, Circuit Judge for the United States Court of Appeals for the Federal Circuit keynotes this year's program along with the Honorable Judge Sally Gardner Lane, Administrative Patent Judge, Trial Division, Board of Patent Appeals and Interferences.

Find program topics and speakers below.  Click here for the full agenda.  

Picking the Best Tools From Your Tool Box: Responding Strategically to Freedom To Operate Obstacles Under the AIA                                                                  

Eldora L. Ellison, Ph.D., Director, Sterne, Kessler, Goldstein & Fox
Eric K. Steffe, Director, Sterne, Kessler, Goldstein & Fox
Todd Spalding, Assistant General Counsel, Bristol-Myers Squibb

The Unitary European Patent                                        

Hugh Goodfellow, Partner, Carpmaels & Ransford

Cases To Watch                                                                                                      

John F. Murphy, PhD, Associate, Woodcock Washburn LLP

Amy Nelson, Associate Solicitor, U.S. Patent & Trademark Office
Erica Olson, Senior Counsel, Amgen Inc.
John Paolino, Chief IP Law Counsel, Orthofix International N.V.

Pitfalls and Perplexities of Biotech Patenting                                                                                                 

Peter Knudsen, Ph.D., Partner, Woodcock Washburn LLP

Paul Golian, Assistant General Counsel, Bristol-Myers Squibb
William F. Smith, Of Counsel, Woodcock Washburn LLP and former Administrative Patent Judge, U.S. Patent & Trademark Office
Jean C. Witz, Supervisory Patent Examiner, Technology Center 1600, U.S. Patent & Trademark Office

How Do You Infringe a Pharmaceutical Method Claim?                                                                                                    

Howard W. Levine, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Robert F. Shaffer, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Charles M. Kinzig, Vice President, Corporate IP, GlaxoSmithKline

Navigating Through a Storm: Challenging Patent Term Adjustment Regulations                                                                                            

Jennifer Johnson, Ph.D., Associate, Finnegan, Henderson, Farabow, Garrett & Dunnr LLP
Jeffrey A. Lamken, Partner, Molo Lamken

The Trade Secret Minefield                                                                                                       

Eric J. Marandett, Partner, Choate Hall & Stewart LLP

Philip Chase, General Counsel, Adimab
Daniel Darnley, Vice President & Chief IP Counsel, Millennium: The Takeda Oncology Company

Will Prometheus & Myriad Change the World? What Do They Really Mean For the Biotechnology Industry?                                                                                                   

Brenda Herschbach Jarrell, Ph.D., Partner, Choate Hall & Stewart LLP

Karla Weyand, Managing IP Counsel, Siemens Corp.
Richard Marsh, Executive Vice President, General Counsel & Secretary, Myriad Genetics, Inc.